Werewolf Therapeutics (NASDAQ:HOWL) Releases Earnings Results, Beats Estimates By $0.15 EPS

Werewolf Therapeutics (NASDAQ:HOWL) issued its quarterly earnings results on Friday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.15, FiscalAI reports.

Werewolf Therapeutics Trading Down 5.1%

NASDAQ:HOWL traded down $0.04 during midday trading on Friday, hitting $0.82. The stock had a trading volume of 38,357 shares, compared to its average volume of 437,892. The stock has a 50-day moving average of $0.69 and a 200 day moving average of $1.03. The company has a market capitalization of $39.75 million, a price-to-earnings ratio of -0.51 and a beta of 0.78. Werewolf Therapeutics has a one year low of $0.53 and a one year high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. HC Wainwright dropped their price objective on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a report on Friday, December 19th. Citigroup downgraded Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, January 21st. Finally, Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price target on the stock. in a research note on Friday, December 19th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.75.

Insider Buying and Selling at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Luke Evnin sold 58,980 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $0.57, for a total value of $33,618.60. Following the completion of the sale, the director directly owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. This represents a 2.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders sold 499,420 shares of company stock valued at $296,825. 23.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Qube Research & Technologies Ltd purchased a new stake in Werewolf Therapeutics in the second quarter worth about $48,000. Regal Investment Advisors LLC grew its holdings in Werewolf Therapeutics by 93.3% during the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its position in Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the period. AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Susquehanna International Group LLP raised its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.